002294 信立泰
已收盘 10-29 15:00:00
资讯
新帖
简况
股市必读：信立泰新发布《关于回购公司股份的进展公告》
证券之星 · 05:48
股市必读：信立泰新发布《关于回购公司股份的进展公告》
信立泰（002294）披露2026年三季度报告，10月27日股价下跌0.69%
证券之星 · 10-27 19:10
信立泰（002294）披露2026年三季度报告，10月27日股价下跌0.69%
信立泰(002294)9月30日股东户数8.32万户，较上期减少2.82%
证券之星 · 10-26
信立泰(002294)9月30日股东户数8.32万户，较上期减少2.82%
图解信立泰三季报：第三季度单季净利润同比增长19.24%
证券之星 · 10-26
图解信立泰三季报：第三季度单季净利润同比增长19.24%
信立泰(002294.SZ)发布前三季度业绩，归母净利润6.44亿元，同比增长10.93%
智通财经 · 10-26
信立泰(002294.SZ)发布前三季度业绩，归母净利润6.44亿元，同比增长10.93%
股市必读：信立泰新发布《关于JK06境内临床试验申请获得受理的公告》
证券之星 · 10-26
股市必读：信立泰新发布《关于JK06境内临床试验申请获得受理的公告》
信立泰最新公告：JK06境内临床试验申请获受理
证券之星 · 10-23
信立泰最新公告：JK06境内临床试验申请获受理
10月22日信立泰跌5.20%，光大健康优加混合A基金重仓该股
证券之星 · 10-22
10月22日信立泰跌5.20%，光大健康优加混合A基金重仓该股
信立泰（002294）10月19日主力资金净买入7433.11万元
证券之星 · 10-20
信立泰（002294）10月19日主力资金净买入7433.11万元
信立泰（002294）10月15日主力资金净买入396.34万元
证券之星 · 10-16
信立泰（002294）10月15日主力资金净买入396.34万元
股市必读：信立泰新发布《关于回购公司股份的进展公告》
证券之星 · 10-12
股市必读：信立泰新发布《关于回购公司股份的进展公告》
信立泰（002294）披露回购公司股份进展公告，10月9日股价上涨2.59%
证券之星 · 10-09
信立泰（002294）披露回购公司股份进展公告，10月9日股价上涨2.59%
信立泰（002294）9月30日主力资金净卖出1481.77万元
证券之星 · 10-08
信立泰（002294）9月30日主力资金净卖出1481.77万元
股市必读：信立泰新发布《第六届董事会第二十一次会议决议公告》
证券之星 · 10-08
股市必读：信立泰新发布《第六届董事会第二十一次会议决议公告》
信立泰(002294.SZ)拟4.27亿元回购子公司信泰医疗6.14%股权
智通财经 · 09-18
信立泰(002294.SZ)拟4.27亿元回购子公司信泰医疗6.14%股权
公司问答丨信立泰：JK06为抗肿瘤ADC药物 目前进展顺利
格隆汇 · 09-16
公司问答丨信立泰：JK06为抗肿瘤ADC药物 目前进展顺利
信立泰：JK07已读出II期临床研究Part A期中分析数据
证券之星 · 09-16
信立泰：JK07已读出II期临床研究Part A期中分析数据
信立泰：截至2026年7月31日，公司股东人数88616
证券之星 · 09-16
信立泰：截至2026年7月31日，公司股东人数88616
信立泰重启H股IPO，创新药收入站上半壁江山，仍存单品依赖隐忧
蓝鲸财经 · 09-10
信立泰重启H股IPO，创新药收入站上半壁江山，仍存单品依赖隐忧
8家公司递表，梅卡曼德刷新年内板块认购纪录
同花顺 · 09-07
8家公司递表，梅卡曼德刷新年内板块认购纪录
加载更多
公司概况
公司名称：
深圳信立泰药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-09-10
主营业务：
深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心脑血管、肾脏、代谢类药物及医疗器械、骨科药物、头孢类抗生素及原料。
发行价格：
41.98
{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"信立泰","latestPrice":30.25,"timestamp":1793257383000,"preClose":30.24,"halted":0,"volume":11177583,"delay":0,"changeRate":0.0003,"floatShares":1115000000,"shares":1115000000,"eps":0.6414,"marketStatus":"已收盘","change":0.01,"latestTime":"10-29 15:00:00","open":30.14,"high":30.85,"low":29.8,"amount":339000000,"amplitude":0.0347,"askPrice":30.25,"askSize":53,"bidPrice":30.24,"bidSize":124,"shortable":0,"etf":0,"ttmEps":0.6414,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793323800000},"marketStatusCode":5,"adr":0,"adjPreClose":30.24,"symbolType":"stock","openAndCloseTimeList":[[1793237400000,1793244600000],[1793250000000,1793257200000]],"highLimit":33.26,"lowLimit":27.22,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"isCdr":false,"pbRate":3.89,"roa":"--","peRate":47.162457,"roe":"7.23%","epsLYR":0.58,"committee":0.669755,"marketValue":33723000000,"turnoverRate":0.01,"status":0,"floatMarketCap":33716000000},"requestUrl":"/m/hq/s/002294","defaultTab":"news","newsList":[{"id":"2679375932","title":"股市必读：信立泰新发布《关于回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2679375932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679375932?lang=zh_cn&edition=full","pubTime":"2026-10-30 05:48","pubTimestamp":1793310515,"startTime":"0","endTime":"0","summary":"公司公告汇总：截至2026年10月29日，信立泰已回购股份8,577,140股，占总股本0.77%，成交总金额27,395.79万元。公司公告汇总关于回购公司股份的进展公告深圳信立泰药业股份有限公司于2026年5月29日召开第六届董事会第十九次会议，审议通过回购公司股份的议案，拟以自有资金及自筹资金回购公司A股股份，回购金额不低于30,000万元且不超过50,000万元，回购价格不超过45元/股，实施期限为董事会审议通过之日起不超过12个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000008993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0187","BK0183","BK0188","BK0239","002294","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678791691","title":"信立泰（002294）披露2026年三季度报告，10月27日股价下跌0.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678791691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678791691?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:10","pubTimestamp":1793099443,"startTime":"0","endTime":"0","summary":"截至2026年10月27日收盘，信立泰报收于30.43元，较前一交易日下跌0.69%，最新总市值为339.24亿元。该股当日开盘31.1元，最高31.35元，最低30.3元，成交额达2.89亿元，换手率为0.84%。公司于2026年10月27日披露《2026年三季度报告》。报告显示，本报告期营业收入1,263,642,115.72元，同比增长13.81%；归属于上市公司股东的净利润257,108,810.98元，同比增长19.24%。年初至报告期末营业收入3,742,777,875.90元，同比增长15.47%；归属于上市公司股东的净利润644,200,537.73元，同比增长10.93%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700036520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","BK0028","BK0188","BK0196","BK0239","002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678169733","title":"信立泰(002294)9月30日股东户数8.32万户，较上期减少2.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678169733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678169733?lang=zh_cn&edition=full","pubTime":"2026-10-26 17:55","pubTimestamp":1793008558,"startTime":"0","endTime":"0","summary":"证券之星消息，近日信立泰披露，截至2026年9月30日公司股东户数为8.32万户，较9月10日减少2417.0户，减幅为2.82%。在化学制药行业个股中，信立泰股东户数高于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年9月10日至2026年9月30日，信立泰区间跌幅为1.22%，在此期间股东户数减少2417.0户，减幅为2.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600024220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0239","BK0196","BK0028","BK0183","BK0188","002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678169804","title":"图解信立泰三季报：第三季度单季净利润同比增长19.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678169804","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678169804?lang=zh_cn&edition=full","pubTime":"2026-10-26 17:40","pubTimestamp":1793007657,"startTime":"0","endTime":"0","summary":"证券之星消息，信立泰2026年三季报显示，前三季度公司主营收入37.43亿元，同比上升15.47%；归母净利润6.44亿元，同比上升10.93%；扣非净利润6.25亿元，同比上升10.21%；其中2026年第三季度，公司单季度主营收入12.64亿元，同比上升13.81%；单季度归母净利润2.57亿元，同比上升19.24%；单季度扣非净利润2.24亿元，同比上升1.68%；负债率21.75%，投资收益4736.95万元，财务费用1482.21万元，毛利率74.19%。财报数据概要请见下图:本文数据来源于信立泰2026年三季报，仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600023614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678150209","title":"信立泰(002294.SZ)发布前三季度业绩，归母净利润6.44亿元，同比增长10.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678150209","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678150209?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:04","pubTimestamp":1793001868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)发布2026年第三季度报告，公司前三季度实现营业收入37.43亿元，同比增长15.47%;归属于上市公司股东的净利润6.44亿元，同比增长10.93%;归属于上市公司股东的扣除非经常性损益的净利润6.25亿元，同比增长10.21%;基本每股收益0.58元。2026年前三季度，创新产品商业化梯队不断丰富并逐步放量，推动营业收入和净利润的持续增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512332.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678713635","title":"股市必读：信立泰新发布《关于JK06境内临床试验申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678713635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678713635?lang=zh_cn&edition=full","pubTime":"2026-10-26 01:58","pubTimestamp":1792951092,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘，信立泰报收于30.79元，上涨2.98%，换手率1.3%，成交量14.44万手，成交额4.35亿元。公司公告汇总：信立泰创新药JK06注射液境内临床试验申请获国家药监局受理，拟用于肺癌和乳腺癌等实体瘤治疗。JK06为一种选择性靶向5T4的双表位抗体药物偶联物，拟用于肺癌和乳腺癌等实体瘤治疗。本次申请受理后尚需取得临床试验默示许可，并按相关规定开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0239","BK0028","BK0196","BK0183","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677926090","title":"信立泰最新公告：JK06境内临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2677926090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677926090?lang=zh_cn&edition=full","pubTime":"2026-10-23 19:10","pubTimestamp":1792753856,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)公告称，公司收到国家药品监督管理局出具的受理通知书，创新药“JK06注射液”临床试验申请获得受理。JK06为选择性靶向5T4的双表位抗体药物偶联物，适应证拟为包括肺癌和乳腺癌在内的实体瘤。该产品目前正在欧洲部分国家开展I/II期临床试验。本次境内临床申请获受理后，尚需获得临床试验默示许可，存在不确定性，短期内对公司业绩不会产生实际影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300037993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0183","BK0239","BK0028","BK0188","BK0196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677958494","title":"10月22日信立泰跌5.20%，光大健康优加混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677958494","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677958494?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:44","pubTimestamp":1792658684,"startTime":"0","endTime":"0","summary":"证券之星消息，10月22日信立泰跌5.20%，收盘报29.9元，换手率1.4%，成交量15.58万手，成交额4.74亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为光大保德信基金的光大健康优加混合A。光大健康优加混合A目前规模为6.23亿元，最新净值0.7935，较上一交易日上涨0.1%，近一年下跌10.42%。光大健康优加混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200028655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0183","BK0028","BK0239","BK0187","BK0188","002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676963019","title":"信立泰（002294）10月19日主力资金净买入7433.11万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676963019","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676963019?lang=zh_cn&edition=full","pubTime":"2026-10-20 09:09","pubTimestamp":1792458581,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月19日收盘，信立泰报收于31.78元，上涨3.05%，换手率1.93%，成交量21.55万手，成交额6.73亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入3053.09万元，融资偿还4588.52万元，融资净偿还1535.43万元。融券方面，融券卖出500.0股，融券偿还100.0股，融券余量17.34万股，融券余额551.07万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000006269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0183","002294","BK0187","BK0188","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675517845","title":"信立泰（002294）10月15日主力资金净买入396.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675517845","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675517845?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:06","pubTimestamp":1792112769,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月15日收盘，信立泰报收于30.58元，上涨0.49%，换手率1.68%，成交量18.68万手，成交额5.76亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入2732.95万元，融资偿还3252.49万元，融资净偿还519.54万元。融券方面，融券卖出2.2万股，融券偿还100.0股，融券余量17.34万股，融券余额530.26万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600008707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK0028","BK0239","BK0183","002294","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674784526","title":"股市必读：信立泰新发布《关于回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674784526","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674784526?lang=zh_cn&edition=full","pubTime":"2026-10-12 02:47","pubTimestamp":1791744429,"startTime":"0","endTime":"0","summary":"公司公告汇总：截至2026年9月30日，信立泰已回购股份8,319,640股，占总股本0.75%，成交总金额26,617.19万元，回购进展符合方案规定。公司公告汇总关于回购公司股份的进展公告深圳信立泰药业股份有限公司于2026年5月29日召开董事会，审议通过回购公司股份的议案，拟以自有资金及自筹资金回购A股股份，资金总额不低于30,000万元且不超过50,000万元，回购价格不超过45元/股，回购期限为董事会审议通过之日起不超过12个月。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002294","BK0196","BK0188","BK0187","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674307298","title":"信立泰（002294）披露回购公司股份进展公告，10月9日股价上涨2.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674307298","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674307298?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:43","pubTimestamp":1791539022,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，信立泰报收于30.93元，较前一交易日上涨2.59%，最新总市值为344.81亿元。该股当日开盘30.15元，最高31.15元，最低29.68元，成交额达3.21亿元，换手率为0.95%。公司于2026年10月9日披露《关于回购公司股份的进展公告》。本次回购股份将用于实施股权激励或员工持股计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900027995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0183","BK0188","002294","BK0196","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673807041","title":"信立泰（002294）9月30日主力资金净卖出1481.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673807041","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673807041?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:09","pubTimestamp":1791421776,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月30日收盘，信立泰报收于30.66元，上涨2.37%，换手率1.0%，成交量11.15万手，成交额3.41亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入2630.68万元，融资偿还2512.98万元，融资净买入117.7万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800003048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0183","BK0188","BK0187","BK0196","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673942014","title":"股市必读：信立泰新发布《第六届董事会第二十一次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673942014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673942014?lang=zh_cn&edition=full","pubTime":"2026-10-08 01:14","pubTimestamp":1791393251,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘，信立泰报收于30.66元，上涨2.37%，换手率1.0%，成交量11.15万手，成交额3.41亿元。公司公告汇总：信立泰董事会审议通过《2025年度环境、社会和公司治理报告》。公司公告汇总第六届董事会第二十一次会议决议公告深圳信立泰药业股份有限公司第六届董事会第二十一次会议于2026年9月29日以书面方式召开，会议应参与董事9人，实际参与9人，符合法定人数。公告披露指定媒体为巨潮资讯网。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800000784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0196","BK0188","BK0183","002294","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668946222","title":"信立泰(002294.SZ)拟4.27亿元回购子公司信泰医疗6.14%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2668946222","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668946222?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:16","pubTimestamp":1789719390,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)发布公告，近日，根据原协议约定的回购条款，鉴于信泰医疗未在协议约定期限内实现合格首次公开发行，公司拟按约定履行股权回购义务，并与投资方签署《转让协议》。公司将按约定，以自筹资金人民币4.27亿元回购投资方持有的信泰医疗合计6.1424%股权。回购完成后，公司对信泰医疗的持股比例将由87.3639%增至93.5063%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信立泰(002294.SZ)拟4.27亿元回购子公司信泰医疗6.14%股权","news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0196","BK0028","BK0188","BK0187","002294","159891","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667601912","title":"公司问答丨信立泰：JK06为抗肿瘤ADC药物 目前进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2667601912","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667601912?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:30","pubTimestamp":1789551008,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["002294","BK0183","BK0188","BK0187","BK0196","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667060934","title":"信立泰：JK07已读出II期临床研究Part A期中分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2667060934","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667060934?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:48","pubTimestamp":1789548490,"startTime":"0","endTime":"0","summary":"投资者提问：请问JK07目前什么情况？JK07已读出II期临床研究Part A的期中分析数据，正在进行Part B阶段的研究。Part A阶段结果显示，JK07在充分使用指南推荐的心衰治疗药物的基础上，在LVEF、KCCQ和6MWD等指标呈不同程度的改善趋势。JK07的整体安全性与给药剂量和频次呈明显相关性。JK07后期临床开发计划将根据完整的II期试验有效性和安全性结果来确定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600026327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","002294","BK0187","BK0188","BK0028","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667606130","title":"信立泰：截至2026年7月31日，公司股东人数88616","url":"https://stock-news.laohu8.com/highlight/detail?id=2667606130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667606130?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:33","pubTimestamp":1789547606,"startTime":"0","endTime":"0","summary":"证券之星消息，信立泰(002294)09月16日在投资者关系平台上答复投资者关心的问题。投资者提问：截止到2026年7月31日，公司股东人数是多少信立泰回复：尊敬的投资者您好，感谢您对公司的关注！截至2026年7月31日，公司股东人数88616。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600025949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","002294","BK0187","BK0239","BK0196","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666648561","title":"信立泰重启H股IPO，创新药收入站上半壁江山，仍存单品依赖隐忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2666648561","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666648561?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:29","pubTimestamp":1789032552,"startTime":"0","endTime":"0","summary":"业务层面，信立泰转型取得阶段性成果的同时，核心产品收入集中的风险始终悬而未决。作为转型最重要的产品，信立坦2024 年销售额约 15 亿元，是公司创新药板块最主要的收入来源，公司创新药板块收入高度依赖这一款降压药物。虽然后续信超妥、复立坦、复立安等多款创新产品陆续获批、纳入医保，形成产品梯队，但是这些新产品体量尚小，短期内难以替代信立坦的收入贡献，公司仍然处于单品依赖阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789029785904368871","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["MEDX","002294","LNGR","BK1161","BK0187","KCE","BK0028","IBBQ","BK0188","06978","BK4127","BK0183","BK0239","159992","IPOS","REDS","BK1574","FRHC","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665663318","title":"8家公司递表，梅卡曼德刷新年内板块认购纪录","url":"https://stock-news.laohu8.com/highlight/detail?id=2665663318","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665663318?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:37","pubTimestamp":1788770220,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者吴歌 Wind数据显示，8月31日—9月6日有8家公司向港交所递表，另有1家公司通过聆讯，3家公司招股及2只新股上市。从行业分布看，递表企业覆盖高端制造、车载光学、生物医药 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260907/c679658502.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260907/c679658502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0188","BK0196","BK0187","BK0028","BK0183","002294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793319029442,"stockEarnings":[{"period":"1week","weight":0.0117},{"period":"1month","weight":0.01},{"period":"3month","weight":-0.091},{"period":"6month","weight":-0.4007},{"period":"1year","weight":-0.4593},{"period":"ytd","weight":-0.3797}],"compareEarnings":[{"period":"1week","weight":-0.0018},{"period":"1month","weight":-0.0467},{"period":"3month","weight":-0.0472},{"period":"6month","weight":-0.112},{"period":"1year","weight":-0.0909},{"period":"ytd","weight":-0.08}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"83193人(较上一季度减少2.82%)","perCapita":"13397股","listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","registeredCapital":"111481万元","survey":" 深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心脑血管、肾脏、代谢类药物及医疗器械、骨科药物、头孢类抗生素及原料。","listedPrice":41.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信立泰,002294,信立泰股票,信立泰股票老虎,信立泰股票老虎国际,信立泰行情,信立泰股票行情,信立泰股价,信立泰股市,信立泰股票价格,信立泰股票交易,信立泰股票购买,信立泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}